1: Ghosh P, Schmitz M, Pandurangan T, Zeleke ST, Chan SC, Mosior J, Sun L, Palve V, Grassie D, Anand K, Frydman S, Roush WR, Schönbrunn E, Geyer M, Duckett D, Monastyrskyi A. Discovery and design of molecular glue enhancers of CDK12-DDB1 interactions for targeted degradation of cyclin K. RSC Chem Biol. 2024 Oct 11. doi: 10.1039/d4cb00190g. Epub ahead of print. PMID: 39450271; PMCID: PMC11494886.
2: Zhang Z, Li Y, Yang J, Li J, Lin X, Liu T, Yang S, Lin J, Xue S, Yu J, Tang C, Li Z, Liu L, Ye Z, Deng Y, Li Z, Chen K, Ding H, Luo C, Lin H. Dual-site molecular glues for enhancing protein-protein interactions of the CDK12-DDB1 complex. Nat Commun. 2024 Aug 1;15(1):6477. doi: 10.1038/s41467-024-50642-0. PMID: 39090085; PMCID: PMC11294606.
3: Zhu T, Li Q, Zhang Z, Shi J, Li Y, Zhang F, Li L, Song X, Shen J, Jia R. ARID1A loss promotes RNA editing of CDK13 in an ADAR1-dependent manner. BMC Biol. 2024 Jun 5;22(1):132. doi: 10.1186/s12915-024-01927-9. PMID: 38835016; PMCID: PMC11151582.
4: Orhan E, Velazquez C, Tabet I, Fenou L, Rodier G, Orsetti B, Jacot W, Sardet C, Theillet C. CDK inhibition results in pharmacologic BRCAness increasing sensitivity to olaparib in BRCA1-WT and olaparib resistant in Triple Negative Breast Cancer. Cancer Lett. 2024 May 1;589:216820. doi: 10.1016/j.canlet.2024.216820. Epub 2024 Apr 3. PMID: 38574883.
5: Houles T, Boucher J, Lavoie G, MacLeod G, Lin S, Angers S, Roux PP. The CDK12 inhibitor SR-4835 functions as a molecular glue that promotes cyclin K degradation in melanoma. Cell Death Discov. 2023 Dec 16;9(1):459. doi: 10.1038/s41420-023-01754-x. PMID: 38104154; PMCID: PMC10725499.
6: Schmitz M, Kaltheuner IH, Anand K, Düster R, Moecking J, Monastyrskyi A, Duckett DR, Roush WR, Geyer M. The reversible inhibitor SR-4835 binds Cdk12/cyclin K in a noncanonical G-loop conformation. J Biol Chem. 2024 Jan;300(1):105501. doi: 10.1016/j.jbc.2023.105501. Epub 2023 Nov 26. PMID: 38016516; PMCID: PMC10767194.
7: Bai Y, Liu Z, Li Y, Zhao H, Lai C, Zhao S, Chen K, Luo C, Yang X, Wang F. Structural Mass Spectrometry Probes the Inhibitor-Induced Allosteric Activation of CDK12/CDK13-Cyclin K Dissociation. J Am Chem Soc. 2023 May 31;145(21):11477-11481. doi: 10.1021/jacs.3c01697. Epub 2023 May 19. PMID: 37207290.
8: Liu S, Wu J, Lu X, Guo C, Zheng Q, Wang Y, Hu Q, Bian S, Luo L, Cheng Q, Liu Z, Dai W. Targeting CDK12 obviates the malignant phenotypes of colorectal cancer through the Wnt/β-catenin signaling pathway. Exp Cell Res. 2023 Jul 1;428(1):113613. doi: 10.1016/j.yexcr.2023.113613. Epub 2023 Apr 24. PMID: 37100369.
9: Dai W, Wu J, Peng X, Hou W, Huang H, Cheng Q, Liu Z, Luyten W, Schoofs L, Zhou J, Liu S. CDK12 orchestrates super-enhancer-associated CCDC137 transcription to direct hepatic metastasis in colorectal cancer. Clin Transl Med. 2022 Oct;12(10):e1087. doi: 10.1002/ctm2.1087. PMID: 36254394; PMCID: PMC9577262.
10: Wu Z, Wang M, Li F, Wang F, Jia J, Feng Z, Huo X, Yang J, Jin W, Sa R, Gao W, Yu L. CDK13-Mediated Cell Cycle Disorder Promotes Tumorigenesis of High HMGA2 Expression Gastric Cancer. Front Mol Biosci. 2021 Aug 26;8:707295. doi: 10.3389/fmolb.2021.707295. PMID: 34513922; PMCID: PMC8427521.
11: Li Y, Zhang H, Li Q, Zou P, Huang X, Wu C, Tan L. CDK12/13 inhibition induces immunogenic cell death and enhances anti-PD-1 anticancer activity in breast cancer. Cancer Lett. 2020 Dec 28;495:12-21. doi: 10.1016/j.canlet.2020.09.011. Epub 2020 Sep 15. PMID: 32941949.
12: Hopkins JL, Zou L. Induction of BRCAness in Triple-Negative Breast Cancer by a CDK12/13 Inhibitor Improves Chemotherapy. Cancer Cell. 2019 Nov 11;36(5):461-463. doi: 10.1016/j.ccell.2019.10.012. PMID: 31715127.
13: Quereda V, Bayle S, Vena F, Frydman SM, Monastyrskyi A, Roush WR, Duckett DR. Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer. Cancer Cell. 2019 Nov 11;36(5):545-558.e7. doi: 10.1016/j.ccell.2019.09.004. Epub 2019 Oct 24. PMID: 31668947.